Schroder Investment Management Group
ATRA icon

Schroder Investment Management Group’s Atara Biotherapeutics ATRA Stock Holding History

Schroder Investment Management Group’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,305
Closed -$221K – 1281
2022
Q3 		$221K Buy
+2,305
New +$259K ﹤0.01% 1231
2015
Q4 		– Sell
-937
Closed -$737K – 1179
2015
Q3 		$737K Buy
937
+385
+70% +$470K ﹤0.01% 937
2015
Q2 		$711K Buy
+552
New +$633K ﹤0.01% 944

Other funds holding ATRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Maverick Capital
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Schroder Investment Management Group's ATRA Position: Q4 2022 in Review

Schroder Investment Management Group sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 2,305 shares — an estimated $221K sold.

Schroder Investment Management Group first reported a position in ATRA in Q2 2015 and held it in 3 quarters. The position peaked at $737K in Q3 2015. 138 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

  • Schroder Investment Management Group reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Schroder Investment Management Group sold 2,305 Atara Biotherapeutics shares in Q4 2022, an estimated $221K.
  • Schroder Investment Management Group first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 3 quarters.
  • Schroder Investment Management Group's Atara Biotherapeutics position peaked at $737K in Q3 2015.
  • 138 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on Schroder Investment Management Group's 13F filing for Q4 2022, filed 10 Feb 2023.